The drug, which garnered national attention in March when it was touted by President Donald Trump, has been a subject of scrutiny as conflicting studies emerge on its efficacy in treating COVID-19. Small studies suggesting the drug could be a helpful treatment for the disease have been outweighed by larger studies revealing evidence that the drug was not effective and caused heart problems in some COVID-19 patients.
WHO’s announcement comes two days after the FDA rescinded its emergency use authorization for hydroxychloroquine and chloroquine, citing the same reasons as WHO.
More articles on practice management:
New York neurosurgeon featured in Netflix docuseries ‘Lenox Hill’
Where Medtronic’s 2nd-largest segment is doubling down — 5 VP insights
California hospital acquires endoscopic spine surgery system
